A modified fragment of human growth hormone (amino acids 177-191) studied for its lipolytic properties without affecting IGF-1 or insulin sensitivity.
AOD-9604 stands for "Advanced Obesity Drug" — not the most creative name, but it tells you exactly what this peptide was designed for. It's a synthetic fragment of human growth hormone, specifically the tail end (amino acids 177–191) with an extra tyrosine tacked onto the front. Developed by Metabolic Pharmaceuticals out of Australia, the whole idea was to isolate the fat-burning properties of growth hormone while leaving behind the parts that mess with blood sugar and promote unwanted growth.
How does it work? It ramps up lipolysis (fat breakdown) and puts the brakes on lipogenesis (fat creation) through the beta-3 adrenergic receptor pathway. What makes it interesting is everything it doesn't do: it doesn't bind the GH receptor, doesn't spike IGF-1, and doesn't touch insulin sensitivity or blood glucose. That selectivity is rare.
The animal data is solid — obese Zucker rats lost significant fat without losing lean mass [1]. Phase 2 human trials showed statistically significant weight loss over placebo [3]. And in a fairly unusual move for a peptide, the FDA granted it GRAS status in 2010 as a food supplement ingredient.
AOD-9604 burns fat through a completely different route than full-length growth hormone. Here's how each piece works:
AOD-9604 hits the beta-3 adrenergic receptor (ADRB3) on fat cells. This receptor lives primarily in visceral and brown adipose tissue. Once activated, it kicks off the cAMP-PKA cascade, which lights up hormone-sensitive lipase (HSL) and starts breaking triglycerides down into free fatty acids and glycerol — the building blocks your body can actually burn for energy [1].
It's not just breaking fat down — it's also blocking your body from making new fat. AOD-9604 dials back acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS), the two enzymes that gate-keep new fat production. So you're hitting both sides of the equation at once: more fat out, less fat in. Most fat-loss agents only do one or the other [2].
This is really the selling point of AOD-9604: it's what the peptide doesn't do. No GH receptor binding. No IGF-1 elevation. No insulin sensitivity changes. No blood glucose swings. No bone growth effects. You get the fat metabolism benefits without the diabetes risk and acromegaly concerns that come with injecting full-length growth hormone.
Here's a bonus nobody expected: AOD-9604 seems to help cartilage too. It stimulates proteoglycan synthesis in joint cartilage, which has opened up a whole new line of osteoarthritis research. This appears to be completely separate from the fat metabolism pathway — likely a different receptor interaction altogether.
Timing matters with AOD-9604 — you want an empty stomach. Eating, especially fats and carbs, can blunt the lipolytic response and undercut what the peptide is trying to do.
| Protocol | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Standard | 300 mcg | Once daily, AM fasted | 12 weeks | Most commonly referenced in literature |
| Split dose | 150 mcg | Twice daily (AM + pre-sleep) | 12 weeks | Mimics pulsatile pattern |
| Cycle | 300 mcg/day | Once daily | 12 weeks on, 4 off | Standard cycling approach |
AOD-9604 reconstitutes easily with bacteriostatic water. It dissolves fast and doesn't need much coaxing.
2 mL of bacteriostatic water into a sterile syringe. For a 5 mg vial, this yields a concentration of 2,500 mcg/mL.5 mg vial + 2 mL BAC water: Concentration = 2,500 mcg/mL
300 mcg dose = 12 units (0.12 mL) on a 100-unit insulin syringe
150 mcg dose = 6 units (0.06 mL) on a 100-unit insulin syringe
Doses per vial: ~16 doses at 300 mcg, or ~33 doses at 150 mcg
AOD-9604 goes subcutaneous (SubQ). For fat-loss work, most people inject into the abdomen — there's a logic to putting it near the fat you're targeting, though the peptide works systemically either way.
Move your injection sites around to avoid lipodystrophy (weird fat tissue changes under the skin). A clock pattern around the navel works well. The good news is that AOD-9604 volumes are tiny (0.12 mL), so the injection is over before you know it. Keep at least 1 inch between sites.
Nothing unusual here — standard peptide storage rules apply. Get this right and your vials will stay potent through the full cycle.
Safety-wise, AOD-9604 looks about as clean as a peptide can. In both animal studies and Phase 2 human trials, side effects tracked right alongside placebo.
AOD-9604 is a research peptide. Yes, it has GRAS status from the FDA for food supplement use, but it's not approved as a pharmaceutical drug. Everything you've read here comes from published research — it's not medical advice.
AOD-9604 plays well with others. Here are the combinations that show up most often in body composition research.
This is a popular three-way combo. AOD-9604 handles the direct fat burning, while Ipamorelin and CJC-1295 boost your own growth hormone output to support lean mass. Since all three work through completely different pathways, there's no receptor competition — they don't step on each other's toes.
| Peptide | Dose | Frequency | Duration |
|---|---|---|---|
| AOD-9604 | 300 mcg | Once daily (AM fasted) | 12 weeks |
| Ipamorelin | 200 mcg | 2–3x daily (fasted) | 8–12 weeks |
| CJC-1295 (no DAC) | 100 mcg | 2–3x daily with Ipamorelin | 8–12 weeks |
A peptide isn't a magic bullet. These lifestyle factors can make a real difference in how much you get out of AOD-9604:
AOD-9604 is available in 5 mg vials from Heritage Labs USA, a U.S.-based research peptide supplier with batch-level purity verification.